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41. The myocardial protective effect of dexmedeto-
midine in high risk patients undergoing aortic
vascular surgery
R. Soliman
Cairo University, Giza, Egypt
Dexmedetomidine provides perioperative cardiac pro-
tection in high risk patients assessment the effect of dex-
medetomidine in high risk patients undergoing aortic
vascular surgery. Arandomized study included 150
patients classified into two groups(n = 75). Group D:
The patients received a loading dose of 1 lg/kg dexme-
detomidine over 15 min before induction and maintained
as an infusion of 0.3 lg/kg/hr to the end of the procedure.
Group C: The patients received an equal volume of nor-
malsaline. The dexmedetomidine decreased heart rate
and minimized the changes in blood pressure compared
to control group (p < 0.05). Also, it decreased the inci-
dence of myocardial is chemia reflected by troponin I
level and ECG changes(p < 0.05). Dexmedetomidine
decreased the requirement for nitroglycerine and norepi-
nephrine compared to control group (p < 0.05). The inci-
dence of hypotension and bradycardia were
significantly higher with dexmedetomidine (p < 0.05).
The dexmedetomidine is safe and effective in patients
undergoing aortic vascular surgery. It decreases the
changes in heart rate and blood pressure during the pro-
cedures. It provide scardiac protection in high risk
patients reflected by decreasing the incidence of myocar-
dial ischemia and serum level of troponin. The main side
effects of dexmedetomidine were hypotension and
bradycardia.
http://dx.doi:10.1016/j.jsha.2016.04.042
Microcirculation and Cerebral/Coronary/peripheral
circulation
42. The effect of ticagrelor on coronary blood after
primary PCI when compared with clopidogril
W. Kadro
The Golden Center for Cardiovascular Research,
Damascus, Syrian Arab Republic
Primary PCI (PPCI) has been established as the best
treatment for acute MI when it is used appropriately. It is
known to give better TIMI III flow and better frame count
when compared with thrombolytics. Loading with P2Y12
inhibitors in the ER prior to primary PCI is an important
step in antiplatelet therapy for acute myocardial infarction.
In this studyWe report the effect of loadingwith two differ-
ent P2Y12 inhibitors (ticagrelor and clopidogril) on theTIMI
frame count in the culprit artery after successful PPCI. Tica-
grelor may affect coronary microcirculation and coronary
blood flow through faster and stronger platelet inhibition.
We randomized 44 patient who presented to our center
with acute MI into two groups. The first group received a
loading with 180mg of ticagrelor and the second group
received a loading with 600 mg of clopidogril. The mean
door to balloon time was 98 ± 12 min. All patients in both
groups received a loading with 162 mg of aspirin. GP IIb/
IIIa inhibitors were used in all cases together with adjusted
dose heparin. Stent usage was 100%. No thrombectomy or
thrombus aspiration device was used in any of these cases.
TIMI III flow after stenting was achieved in all culprit
arteries. Then we calculated the TIMI frame count in the
culprit artery after successful primary PCI. The mean cor-
rected TIMI frame count in the culprit artery post PCI was
18.34 ± 3.16 frames in group 1 (Ticagrelor group) and
28.73 ± 3.92 in group 2 (clopidogril group) (p = 0.02). Load-
ingwith ticagrelor gives faster flow after successful primary
PCI in the culprit artery of acute MI when compared with
clopidogril. This can be explained by the fact that ticagrelor
therapy give faster P2Y12 inhibition thus faster antiplatelet
therapy causing less platelet aggregation resulting in less
distal embolization and reduced production of inflamma-
tory mediators and adhesion molecules which may result
in faster restoration of normal endothelial function. This
finding may partially explain the mortality benefit of tica-
grelor in a previousACS study. A larger prospective rando-
mized study is needed to confirm this finding.
http://dx.doi:10.1016/j.jsha.2016.04.043
Cellular biology function
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PHARMACOLOGY
43. Calmodulin regulating calcium sensitivity of Na
channels
R. Vegiraju
University of Texas at Austin, Austin, USA
By extrapolating information from existing research and
observing previous assumptions regarding the structure of
the Na Channel, this experiment was conducted under the
hypothesis that the Na Channel is in part regulated by the
calmodulin protein, as a result proving calcium sensitivity
of the Na Channel. Furthermore, we assume that there is
a one to one stoichiometry between the Na Channel and
the Calmodulin. There has been extensive research into
the functionality and structure of sodium ion channels
(Na channels), as several diseases are associated with the
lack of regulation of sodium ions, that is caused by the dis-
function of theseNa channels.However, one highly contro-
versial matter in the field is the importance of the protein
calmodulin (CaM) and calcium inNachannel function.Cal-
modulin is a protein that is well known for its role as a cal-
cium binding messenger protein, and that association is
believed to play an indirect role in regulating the Na chan-
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nel through theNa channel’s supposed calcium sensitivity.
While there are proponents for both sides, there has been
relatively little research that provides strong evidence for
either case. In this experiment, the effect of calmodulin on
NaV 1.5 is tested by preparing a set of cardiac cells (of the
human specie) with the NaV 1.5 C-Termini and CaM pro-
tein, whichwere then to be placed in solutionswith varying
concentrations of calcium.We took special care to test mul-
tiple concentrations of calcium, as previous studies have
tested very low concentrations, with Manu Ben-Johny’s
team from the JohnHopkins laboratory in particular testing
up to a meager 50 micromolar, despite producing a well-
respected paper (By comparison, the average Na channel
can naturally sustain a concentration of almost 1-2millimo-
lar and on someoccasions, reaching evenhigher concentra-
tions). After using light scattering and observing the signals
given off by the calcium interactingwith theseNav1.5/CaM
complexes across the varying calcium concentrations, the
overall pattern indicated that there was a one to one stoi-
chiometry between calmodulin and Nav 1.5. More impor-
tantly, it indicated calcium sensitivity of the Na channel.
With this research, a definitive answer has been drawn
regarding the importanceof calmodulin in calciummodula-
tion in Na channels. Not only does this have the effect of
creating a foundation for further research into the structure
and function of Na channels, but it also gives deep insight
into fundamental functions of the channel that can play a
major role into the creation of drugs to treat the many car-
diac diseases associated with dysfunction of the channel.
http://dx.doi:10.1016/j.jsha.2016.04.044
Chronic and acute ischemic heart disease
BIOMARKERS
44. Copeptin as early marker of acute non-ST
elevation myocardial infarction in patients
suspected with acute coronary syndrome
S. Rafla a, S. Azab b, S. Eman c, S. Mohamed d
aAlexandria University, Alexandria,
Egypt; bAlexandria University, Cardiology, Alexandria,
Egypt; cAlexandria University, Clinical Pathology,
Alexandria, Egypt; dAlexandria University, Cardiac
Catheterization Laboratory, Alexandria, Egypt
Rapid diagnosis and management of AMI have great
impact on morbidity and mortality. Diagnosis which is
based on elevation of cardiac biomarkers has its limita-
tions. Copeptin is the C-terminal part of the vasopressin
prohormone. The pathophysiology mode of release
should theoretically add diagnostic information of car-
diac cell necrosis. One of the major limitations of cardiac
biomarkers is the delayed release in circulation. So look-
ing for a new marker with a short diagnostic time window
is needed. Aim is to determine the role of copeptin as an
early marker for acute non-ST elevation MI (NSTEMI).
This study included 88 patients with chest pain. They
were divided into 2 groups. Group (1); included 30
patients with diagnosis of NSTEMI. Diagnosis of AMI
was established according to the universal definition of
MI. Group (2); included 58 patients with diagnosis of
unstable angina (UA). Full medical history, physical
examination, 12 lead ECG, random blood glucose level,
renal function, total cholesterol, triglyceride, cardiac tro-
ponin I and Copeptin were obtained on admission. Fol-
low up cardiac troponin I was done. Inclusion criteria:
Defined as chest pain of 66 h duration since onset, sug-
gestive of myocardial ischemia, and lasting >20 min. at
rest. Exclusion criteria: Patients with positive First cardiac
troponin were rolled out, patients with ST segment eleva-
tion were rolled out. Other exclusion criteria: Patients
presenting after a cardiac arrest, Trauma or major sur-
gery within the last 4 week; pregnancy; IV drug abuse;
age less than 18 years; shock and sepsis. Patients who
were included had second troponin I re- done and copep-
tin analysis done. In group 1 (NSTEMI) 28 patients had
ECG changes and only 2 had NSTEMI without ECG
changes. In group 2 (UA) 23 patients had ECG changes
and 35 patients had normal ECG. Males and females
were 49 and 39. Age in G1 and G2 was 60 ± 4 and
53 ± 5. Copeptin analysis was done 6 h after Infarction
or chest pain. All the patients with NSTEMI (30) had
positive copeptin and positive troponin except one only
who had + troponin only and another one who had +
copeptin only. Of the 58 patients without MI none had
the two tests positive, only one had + troponin and one
had + copeptin. Using ROC curve: copeptin had sensitiv-
ity 100% and specificity 82.8% with using cut off point
13.2 pmol/l. So copeptin can be used for early detection
of myocardial infarction. Copeptin seems to be an ideal
confirmatory marker for rapid rule out of AMI. If the
two tests (with troponin) are positive, this is evident
MI; if the two are negative it rules out MI.
http://dx.doi:10.1016/j.jsha.2016.04.045
Chronic ischemic heart disease
45. Ezetimibe and statins yields on silent holter
ambulatory myocardial ischemia
W. Kadro
The Golden Center for Cardiovascular Research,
Damascus, Syrian Arab Republic
Further cholestrol lowering may affect silent ischemia
detected on holter monitoring. Cholesterol lowering is
associated with a reduction in cardiovascular morbidity
and mortality. Statins are the main drugs for cholesterol
lowering. Ezetimibe when added to statins gives further
reduction in cholesterol but its long-term effect on cardi-
ovascular morbidity and mortality and ischemic events is
not known. This study sought to determine whether
further cholesterol lowering with ezitimibe will also
results in a reduction of myocardial ischemia during daily
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